Adults with relapsing MS rated the Sensoready pen, an autoinjector used to self-administer Kesimpta, for ease of use and ...

The new data presented by Novartis at ECTRIMS 2022 highlighted ... slow down the progression of the disease. Kesimpta is such a drug, taken as an injection under the skin once a month.

Novartis (NOVN.S), opens new tab on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer multiple sclerosis drug Kesimpta ...

Novartis shares jumped 3.6% to a three-month high of 97.15 francs at 0941 GMT, with investors also encouraged by the company's upbeat 2025 earnings projections. Entresto, which will lose patent ...

FRANKFURT (Reuters) -Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer multiple sclerosis drug Kesimpta ...

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator.

FRANKFURT (Reuters) -Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer multiple sclerosis drug Kesimpta exceeded ...

Kesimpta, Kisqali, Cosentyx and Leqvio. The top line beat the Zacks Consensus Estimate of $12.97 billion. Shares are up in response to the quarterly results. Shares of Novartis have risen 1.3% in ...

Novartis forecasts further profit and sales ... cholesterol treatment Leqvio and multiple sclerosis medicine Kesimpta--offset a one-percentage-point hit from generic competition.

Kesimpta is a brand-name subcutaneous injection prescribed for certain forms of multiple sclerosis (MS). Kesimpta begins working right away, but it may take some time for you to notice relief in ...